Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-09-27 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the announcement of the approval of Tezspire in Japan for severe asthma, including clinical trial results and drug information. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. The document is an announcement of a regulatory and product approval event rather than a financial report or management discussion. Form 6-K filings are generally considered regulatory filings for foreign issuers to disclose material information. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content support this classification with high confidence.
2022-09-27 English
Koselugo approved in Japan for NF1
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8019A' and is dated '27 September 2022'. It announces a specific corporate event: the approval of the drug Koselugo in Japan. The structure, including the RNS header, the immediate announcement of news, and the concluding boilerplate text referencing RNS and the London Stock Exchange, strongly indicates this is a regulatory news service announcement. Since this is a specific, material announcement that doesn't fit perfectly into the defined categories like ER (Earnings Release) or DIV (Dividend Notice), and it is clearly a regulatory disclosure distributed via RNS, the most appropriate classification is the general regulatory filing category.
2022-09-27 English
Tezspire approved in Japan for severe asthma
Regulatory Filings Classification · 100% confidence The document is identified by the header 'RNS Number : 6973A' and the presence of the 'National Storage Mechanism' indicator, which are hallmarks of regulatory news service announcements, typically originating from the UK's Financial Conduct Authority (FCA) regulated dissemination services. The content is a press release announcing a specific corporate event: the approval of the drug Tezspire in Japan. This is a material event announcement, not a comprehensive financial report (like 10-K or IR) or a transcript. Since it is a general regulatory announcement that doesn't fit the more specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate classification is the general regulatory filing/announcement category, RNS.
2022-09-27 English
ULTOMIRIS APPROVED IN EU FOR GMG
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Ultomiris in the EU for generalized myasthenia gravis (gMG), including clinical trial results, drug description, and company background. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a significant event (drug approval) relevant to investors. The document length is about 13,000 characters, and it contains substantive content rather than just an announcement or certification. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they are miscellaneous reports by foreign issuers that do not fit other specific categories.
2022-09-23 English
Ultomiris approved in EU for gMG
Regulatory Filings Classification · 100% confidence The document is identified by the header 'RNS Number : 4292A' and concludes with information about RNS, the news service of the London Stock Exchange. The content is a press release announcing the European approval of a drug (Ultomiris) for a specific condition (gMG), detailing clinical trial results and management commentary. This format—a formal announcement of a significant corporate/product event distributed via a regulatory news service—fits best under the general 'Regulatory Filings' category (RNS), as it is not a comprehensive financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV). It is a general regulatory announcement.
2022-09-23 English
LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Lynparza in China for ovarian cancer, including clinical trial results, regulatory approvals, and company statements. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing that provides material information about the company's operations and regulatory status but does not contain financial statements or detailed financial analysis. The document length is 15,000 characters, indicating it is a substantive report rather than a brief announcement. Given the nature of Form 6-K filings, which are used by foreign private issuers to report material information to the SEC, this document fits best under Regulatory Filings (RNS).
2022-09-22 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.